Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0001460

Acetylsalicylic acid for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Acetylsalicylic acid, 2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule linéaire :
2-(CH3CO2)C6H4CO2H
Numéro CAS:
50-78-2
Poids moléculaire :
180.16
Numéro Beilstein :
779271
Numéro MDL:
MFCD00002430
Code UNSPSC :
41116107
ID de substance PubChem :
329831434
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

aspirin

Fabricant/nom de marque

EDQM

Pf

134-136 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

Clé InChI

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Informations sur le gène

human ... PTGS1(5742) , PTGS2(5743)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Acetylsalicylic acid for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

PHR1003

Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material

1044006

Aspirin, United States Pharmacopeia (USP) Reference Standard

A0200000

Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard

1609807

Salsalate, United States Pharmacopeia (USP) Reference Standard

1696200

Trisalicylic acid, United States Pharmacopeia (USP) Reference Standard

BP617

Aspirin, British Pharmacopoeia (BP) Reference Standard

PHR1940

Aspirin Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1941

Aspirin Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1942

Aspirin Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

482.0 °F

Point d'éclair (°C)

250 °C

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Gwen M C Masclee et al.
Gastroenterology, 147(4), 784-792 (2014-06-18)
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB). Guidelines suggest avoiding certain drug combinations, yet little is known about the magnitude of their interactions. We estimated the risk of UGIB
Gideon Sahar et al.
The Journal of thoracic and cardiovascular surgery, 149(4), 1042-1050 (2015-04-25)
We compared the flow rates, reactivity, and morphology of the distal internal thoracic artery and its branches, the superior epigastric and musculophrenic arteries, to test their applicability as possible conduits in coronary artery bypass grafting surgeries. Skeletonized internal thoracic artery
Yu-Chi Tung et al.
Medical care, 52(6), 519-527 (2014-05-03)
A volume-outcome relationship has been found for acute myocardial infarction (AMI); however, the mechanisms underlying the relationship remain unclear. In particular, it is not known whether processes of care are mediators of the volume-outcome relationship, that is, whether the mechanisms
T N Bonten et al.
Thrombosis and haemostasis, 112(6), 1209-1218 (2014-09-12)
The risk of acute cardiovascular events is highest during morning hours, and platelet activity peaks during morning hours. The effect of timing of aspirin intake on circadian rhythm and morning peak of platelet reactivity is not known. It was our
Laurent Arnaud et al.
Autoimmunity reviews, 13(3), 281-291 (2013-11-06)
We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+). Observational and interventional studies identified from the Medline, Embase and Cochrane databases were selected if they
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique